Whitehawk Therapeutics (WHWK) Net Cash Flow (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Net Cash Flow for 17 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 101.4% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$192.8 million (down 210.97% YoY), while the FY2025 annual figure was $8.8 million, up 125.82% from the prior year.
• Net Cash Flow declined to -$2.8 million in Q1 2026 per WHWK's latest filing, from -$363000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $198.8 million in Q1 2025 and bottomed at -$107.0 million in Q3 2025.
• Historically, Net Cash Flow has averaged -$6.7 million across 5 years, with a median of -$5.9 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 1753.98% — and 2025, when it jumped 2283.08%.
• Whitehawk Therapeutics' Net Cash Flow stood at -$95.8 million in 2022, then jumped by 93.83% to -$5.9 million in 2023, then surged by 68.44% to -$1.9 million in 2024, then surged by 80.56% to -$363000.0 in 2025, then slumped by 665.29% to -$2.8 million in 2026.
• Business Quant data shows WHWK's Net Cash Flow at -$2.8 million in Q1 2026, -$363000.0 in Q4 2025, and -$107.0 million in Q3 2025.